A 35-year-old woman with systemic lupus erythematosus (SLE) on long-term hydralazine therapy presents with fever, arthralgia, and a malar rash 18 months after starting the drug. Investigations show positive ANA, elevated ESR, and negative anti-dsDNA antibodies. She has no prior history of SLE exacerbation. What is the most appropriate immediate next step in management?

Explanation

## Clinical Scenario Analysis This patient presents with a drug-induced lupus-like syndrome (DILS) caused by hydralazine — a classic **Type B (Dose-Independent, Predictable) Adverse Drug Reaction** that mimics idiopathic SLE but is reversible upon drug discontinuation. ## Drug-Induced Lupus: Classification & Pathophysiology **Key Point:** Drug-induced lupus is a Type B ADR caused by idiosyncratic immune activation (not dose-dependent toxicity). Hydralazine is one of the most common culprits, particularly in slow acetylators due to accumulation of reactive metabolites. ### Distinguishing Features: Drug-Induced vs. Idiopathic SLE | Feature | Drug-Induced Lupus | Idiopathic SLE | |---------|-------------------|----------------| | **Anti-dsDNA** | Negative | Positive (95%) | | **Anti-histone** | Positive (95%) | Positive (70%) | | **Renal involvement** | Rare | Common (50–80%) | | **CNS involvement** | Rare | Common | | **Reversibility** | Yes (upon drug withdrawal) | No | | **Timeline** | Weeks to months | Variable | | **Common drugs** | Hydralazine, procainamide, isoniazid, minocycline | — | **Mnemonic: HIPPO** — **H**ydralazine, **I**soniazid, **P**rocainamide, **P**henytoin, **O**ther (minocycline, sulfonamides, TNF-α inhibitors) — drugs causing drug-induced lupus. ## Management Algorithm ```mermaid flowchart TD A[Suspected Drug-Induced Lupus]:::outcome --> B{Offending drug identified?}:::decision B -->|Yes| C[Discontinue drug immediately]:::action B -->|No| D[Identify culprit from history] D --> C C --> E[Monitor clinical response over 2-4 weeks]:::action E --> F{Symptoms resolve?}:::decision F -->|Yes| G[Diagnosis confirmed: DILS]:::outcome F -->|No| H[Consider idiopathic SLE or other etiology]:::outcome G --> I[Avoid re-challenge with same drug]:::action H --> J[Immunosuppression if needed]:::action ``` ## Immediate Management Strategy 1. **Drug withdrawal is the cornerstone** — discontinue hydralazine immediately; this is both diagnostic and therapeutic. 2. **Expectation of resolution** — most symptoms (fever, arthralgia, rash) resolve within 2–4 weeks of drug discontinuation. 3. **Supportive care** — NSAIDs or low-dose corticosteroids (if needed) for symptom relief during the washout period. 4. **Monitoring** — repeat ANA and anti-histone antibodies in 4–8 weeks; they typically normalize. 5. **Alternative antihypertensive** — switch to ACE inhibitor, calcium channel blocker, or other agent not associated with DILS. **High-Yield:** The negative anti-dsDNA antibodies and positive ANA (likely with anti-histone positivity, though not tested here) strongly support drug-induced lupus rather than idiopathic SLE. Drug withdrawal is both diagnostic and therapeutic. **Clinical Pearl:** Slow acetylators (genetically determined) are at higher risk for hydralazine-induced lupus because the drug accumulates and undergoes oxidative metabolism to reactive intermediates that trigger immune responses. **Warning:** Do NOT escalate immunosuppression (azathioprine, high-dose corticosteroids) before attempting drug withdrawal — this delays the definitive treatment and masks the diagnosis. [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 430]